Ian W Flinn (Ian W Flynn, Ian Flinn)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 35

Top Topics

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Circulating Tumor

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, Sonali M Smith, Ian W Flinn, Nancy L Bartlett, Nilanjan Ghosh, Gal Hacohen-Kleiman, Yanan Huo, Linda Su-Feher, Camille Renard, Ranjana H Advani, Mark J Roschewski
Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up. Blood advances (2024)
Pinkal M Desai, Sagar Lonial, Amanda F Cashen, Manali Kamdar, Ian W Flinn, Susan M O'Brien, Jacqueline S Garcia, Neha Korde, Javid J Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Marcio Andrade-Campos, Tapan Mahendra Kadia, James S Blachly
A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Joeseph Maakaron, Adam S Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn, Nilanjan Ghosh, Colm Keane, Matthew Ku, Amitkumar Mehta, Mark J Roschewski, Gal Hacohen-Kleiman, Yanan Huo, Yi Zhang, Camille Renard, Sonali M Smith, Ranjana H Advani
Magrolimab Plus Rituximab with/without Chemotherapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood advances (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin Parsons, Paolo F Caimi, Ian W Flinn, Alex F Herrera, Jeffrey Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 143 (16) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Chan Yoon Y Cheah, Connie Y Ma, Huang Huang, Antonia Kwan, Michael C Wei, Shen Yin, Nancy L Bartlett
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (19) (2024)
Jennifer A Woyach, Deborah M Stephens, Ian W Flinn, Seema A Bhat, Ronald E Savage, Feng Chai, Sudharshan Eathiraj, Sean D Reiff, Elizabeth M Muhowski, Lindsey Granlund, Lyndsey Szuszkiewicz, Wayne Wang, Brian Schwartz, Razi Ghori, Mohammed Z H Farooqui, John C Byrd
First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer discovery (2023)
Michael J Dickinson, Pere Barba, Ulrich Jäger, Nirav N Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti, Anne-Laure Marchal, David S Quinn, Jennifer Yang, Andrew Price, Akash Sohoni, Louise M Treanor, Elena J Orlando, Jennifer Mataraza, Jaclyn Davis, Darlene Lu, Xu Zhu, Boris Engels, Laure Moutouh-de Parseval, Jennifer L Brogdon, Michele Moschetta, Ian W Flinn
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development. Cancer discovery (2023)
Michael L Wang, Wojciech Jurczak, Pier Luigi Luigi Zinzani, Toby Andrew Eyre, Chan Yoon Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian W Flinn, Benoît Tessoulin, Alvaro J Alencar, Shuo Ma, David John Lewis, Ewa Lech-Maranda, Joanna M Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S Tam, Tahla Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S Fenske, John Francis Seymour, Andrew D Zelenetz, Binoj Nair, Donald E Tsai, Minna Balbas, Richard A Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R Mato, Nirav N Shah
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mark J Roschewski, Manish R Patel, Patrick M Reagan, Nakhle S Saba, Graham P Collins, Hendrick-Tobias Arkenau, Sven de Vos, Barret R B Nuttall, Melih Acar, Kathleen Burke, Rafael D White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David F Jenkins, Andrew Mortlock, Alessandra Forcina, Veerendra Munugalavadla, Ian W Flinn
Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David Bernard Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abhinav Deol, Patrick M Reagan, Patrick Joseph Stiff, Ian W Flinn, Umar Farooq, Andre H Goy, Peter McSweeney, Javier L Muñoz, Tanya Siddiqi, Julio C Chavez, Alex F Herrera, Nancy L Bartlett, Adrian A Bot, Rhine R Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J Kim, Yan Zheng, Frederick L Locke
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood (2023)
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Yoon Y Cheah, Matthew J Matasar, Gareth Peter Gregory, Dok-Hyun Yoon, Mazyar Shadman, Keith Fay, Sung Soo Yoon, Carlos Panizo, Ian W Flinn, Anna M Johnston, Francesc Bosch, Laurie H Sehn, Michael C Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, L Elizabeth Elizabeth Budde
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood advances (2023)
David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic, Terrence J Bradley, Ian W Flinn, Daniel A Pollyea, Suman Kambhampati, Tiffany N Tanaka, Joshua F Zeidner, Guillermo Garcia Manero, Deepa Jeyakumar, Rami S Komrokji, Jeffrey Lancet, Hagop M Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G Daver
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic, Terrence J Bradley, Ian W Flinn, Daniel A Pollyea, Suman Kambhampati, Tiffany N Tanaka, Joshua F Zeidner, Guillermo Garcia Manero, Deepa Jeyakumar, Rami S Komrokji, Jeffrey Lancet, Hagop M Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark Chao, Carol O'Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval G Daver
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps, Paul M Barr, Anna Elinder Camburn, Alessandra Tedeschi, Xavier C Badoux, Ryan Jacobs, Bryone J Kuss, Livio Trentin, Cathy Zhou, Anita Szoke, Christopher Abbazio, William G Wierda
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Judith Trotman, Loretta J Nastoupil, Pierre Feugier, Jean Marc Schiano De Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N Libby, René-Olivier Casasnovas, Ian W Flinn, Corinne Haioun, Hervé Maisonneuve, Loic Ysebaert, Nancy L Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Stéphanie Guidez, Gian Matteo Pica, Alejandro Martin Martin Garcia-Sancho, Armondo López-Guillermo, Jean-François Larouche, Kiyoshi Ando, Maria Gomes da Silva, Marc André, Ka Lung Wu, Laurie Helen Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H Fowler, Gilles Andre Salles
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (28) (2022)
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Emmanuelle Ferrant, William G Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C Byrd
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 36 (4) (2022)
Michael L Wang, Javier L Muñoz, Andre H Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A McSweeney, David Bernard Miklos, John M Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S Topp, Houot Roch, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R Shen, Rubina Siddiqi, Ioana Kloos, Patrick M Reagan
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre H Goy, Anas Younes, Suresh Bobba, Adrian M Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Patrick Trojer, Jeremy S Abramson
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer research communications 2 (8) (2022)
Tycel Jovelle Phillips, Mark Brunvand, Andy I Chen, James Essell, Annalisa Chiappella, Catherine Diefenbach, Ji Cheng, David Ramies, Jamie Hirata, Franck Morschhauser, Ian W Flinn
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study. American journal of hematology (2021)
L Elizabeth Elizabeth Budde, Sarit E Assouline, Laurie Helen Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, Ian W Flinn, Mazyar Shadman, Catherine S Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C Piccione, Michael C Wei, Shen Yin, Nancy L Bartlett
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (5) (2021)
Jesus G Berdeja, Tara K Gregory, Edward A Faber, Lowell L Hart, Joseph R Mace, Edward R Arrowsmith, Ian W Flinn, Jeffrey V Matous
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. American journal of hematology 96 (4) (2021)
William G Wierda, John N Allan, Tanya Siddiqi, Thomas J Kipps, Stephen Samuel Opat, Alessandra Tedeschi, Xavier C Badoux, Bryone J Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M Pagel, Ian W Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer-Glusman, Joi Ninomoto, James P Dean, Danelle F James, Paolo Ghia, Constantine S Tam
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (34) (2021)
David P Steensma, Martin Wermke, Virginia M Klimek, Peter L Greenberg, Patricia Font, Rami S Komrokji, Jay Yang, Andrew M Brunner, Hetty E Carraway, Lionel Ades, Aref A Al-Kali, Juan M Alonso-Dominguez, Ana Alfonso-Piérola, Catherine C Coombs, H Joachim Deeg, Ian W Flinn, James M Foran, Guillermo Garcia Manero, Michael B Maris, Malgorzata McMasters, Jean-Baptiste Micol, Jaime Perez De Oteyza, Felicitas Thol, Eunice S Wang, Justin M Watts, Justin Taylor, Richard Stone, Vikram Gourineni, Alyssa J Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35 (12) (2021)
Stephen M Ansell, Michael B Maris, Alexander M Lesokhin, Robert W Chen, Ian W Flinn, Ahmed Sawas, Mark D Minden, Diego R Villa, Mary-Elizabeth M Percival, Anjali S Advani, James M Foran, Steven M Horwitz, Matthew G Mei, Jasmine Zain, Kerry J Savage, Christiane Querfeld, Oleg E Akilov, Lisa D S Johnson, Tina Catalano, Penka S Petrova, Robert A Uger, Eric L Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A O'Connor
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (8) (2021)
Nathan H Fowler, Loretta Nastoupil, Sven De Vos, Mark Knapp, Ian W Flinn, Robert Chen, Ranjana H Advani, Sumeet Bhatia, Peter Martin, Raul Mena, Richard Eric Davis, Sattva S Neelapu, Karl Eckert, Jerry Ping, Melannie Co, Darrin M Beaupre, Jutta K Neuenburg, M Lia Palomba
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. British journal of haematology 189 (4) (2020)
Ian W Flinn
PI3K inhibitors and the search for the Holy Grail. Blood 132 (3) (2019)
Ian W Flinn, Mohamad A Cherry, Michael B Maris, Jeffrey V Matous, Jesus G Berdeja, Manish Patel
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. American journal of hematology 94 (12) (2019)
William G Wierda, John C Byrd, Susan O'Brien, Steven Coutre, Paul M Barr, Richard R Furman, Thomas J Kipps, Jan A Burger, Don A Stevens, Jeff Sharman, Paolo Ghia, Ian W Flinn, Cathy Zhou, Joi Ninomoto, Danelle F James, Constantine S Tam
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British journal of haematology 186 (1) (2019)
Ian W Flinn, Dana S Thompson, Ralph V Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven W Papish, Jesus G Berdeja
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. British journal of haematology 180 (3) (2017)